乌帕西卡塞特:一种用于二次性副甲状腺功能障碍的血液透析患者的新型静脉仿剂
Fumihiko Koiwa1, Daisuke Honda2, Seigo Akari3
1Division of Nephrology, Department of Internal Medicine, Showa Medical University Fujigaoka Hospital, Yokohama, Japan.
乌帕西卡塞特是一种新的静脉注射模剂,用于二次性副甲状腺功能障碍症 (SHPT) 的透析患者. 它有效控制SHPT,表现出良好的耐受性和副作用的低发病率,用于长期管理.
科学领域:
- 腎臟病學 (nephrology) 是一種醫學專業.
- 内分泌学 在内分泌学.
- 药理学 药理学 是一个学科.
背景情况:
- 二次性偏甲状腺症 (SHPT) 是维持透析患者的常见并发症.
- 和代谢的干扰是SHPT的主要驱动因素.
- 模仿药对于通过调节感应受体来管理SHPT至关重要.
研究的目的:
- 为了评估Upacicalcet的疗效和安全性,Upacicalcet是一种新的静脉注射仿药.
- 评估Upacicalcet适用于SHPT的血液透析患者的适用性.
- 确定Upacicalcet的长期管理潜力.
主要方法:
- 临床研究涉及有SHPT的血液透析患者.
- 通过静脉注射的Upacicalcet的使用.
- 监测血清完整的副甲状腺激素,纤维细胞生长因子-23和骨周转指数.
主要成果:
- 乌帕西卡塞特有效降低了血清完整的副甲状腺激素水平.
- 在纤维细胞生长因子-23和骨周转标记物中观察到改善.
- 胃肠道症状和低血症的发病率低,具有良好的长期耐受性.
结论:
- 乌帕西卡塞特是一种安全有效的选择,用于在血液透析患者中管理SHPT.
- 它的药物动力学特征 (通过血液透析去除,没有肝脏代谢) 最小化了药物相互作用.
- 持续的生物化学控制和良好的耐受性支持upacicalcet在长期SHPT管理中的作用.
更多相关视频
11:30A Semi-Automated and Reproducible Biological-Based Method to Quantify Calcium Deposition In Vitro
Published on: June 2, 2022
07:13Two Techniques to Create Hypoparathyroid Mice: Parathyroidectomy Using GFP Glands and Diphtheria-Toxin-Mediated Parathyroid Ablation
Published on: March 14, 2017
相关概念视频
Synthesis and Functions of Calcitonin
The exact mechanisms by which calcitonin operates in calcium homeostasis remain elusive, but its significance is evident in several vital...
Hormones and Bone Tissue
Hormones That Influence Osteoblasts and/or Maintain the Matrix
Several hormones are necessary for controlling bone growth and maintaining the bone matrix. The pituitary gland secretes growth hormone (GH), which, as its name implies, controls bone growth. This happens in several ways: first, it triggers chondrocyte...
The Parathyroid Glands
Oxyphil cells, whose functions remain elusive, emerge during late puberty, adding a layer of complexity to the parathyroid gland's intricacies. In contrast, principal parathyroid cells undertake a vital role by...
Skeleton and Calcium Homeostasis
Urinary Tract Calculi II: Pathophysiology and Clinical Manifestations
Hemodialysis III: Nursing Management
